Catalent, Inc. (NYSE:CTLT) Short Interest Update

Catalent, Inc. (NYSE:CTLT) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 8,630,000 shares, a growth of 25.6% from the May 31st total of 6,870,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is currently 5.2 days.

Insider Activity

In related news, insider Ricky Hopson sold 1,401 shares of the business’s stock in a transaction on Tuesday, June 4th. The stock was sold at an average price of $54.26, for a total value of $76,018.26. Following the completion of the sale, the insider now directly owns 20,617 shares in the company, valued at approximately $1,118,678.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.31% of the stock is owned by company insiders.

Institutional Investors Weigh In On Catalent

A number of hedge funds have recently made changes to their positions in CTLT. Lindbrook Capital LLC lifted its stake in Catalent by 79.4% in the 1st quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock valued at $27,000 after purchasing an additional 208 shares during the last quarter. Gladius Capital Management LP acquired a new position in shares of Catalent during the third quarter worth $28,000. GAMMA Investing LLC bought a new position in shares of Catalent in the 4th quarter valued at $33,000. Rakuten Securities Inc. acquired a new stake in shares of Catalent during the 4th quarter valued at $46,000. Finally, Federated Hermes Inc. acquired a new stake in shares of Catalent during the 4th quarter valued at $46,000.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Stephens restated an “equal weight” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, April 4th. StockNews.com began coverage on Catalent in a research report on Sunday. They set a “sell” rating on the stock. Finally, Barclays lifted their price objective on Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a report on Friday. Two analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, Catalent presently has an average rating of “Hold” and an average price target of $55.65.

Catalent Price Performance

NYSE CTLT opened at $56.17 on Tuesday. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20. The business has a fifty day moving average price of $55.56 and a two-hundred day moving average price of $54.06. The company has a debt-to-equity ratio of 1.37, a quick ratio of 1.77 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative return on equity of 2.73% and a negative net margin of 26.61%. The business had revenue of $1.07 billion for the quarter, compared to the consensus estimate of $1.11 billion. As a group, research analysts anticipate that Catalent will post -0.17 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.